期刊文献+

通过医疗档案分析胃肠道间质瘤预后因素

Analysis of prognosis in gastrointestinal stromal tumors
原文传递
导出
摘要 目的分析胃肠道间质瘤预后因素。方法回顾性分析76例胃肠道间质瘤患者的临床病理资料,并建立了随访档案,分析临床病理因素与预后的关系。结果预后因素与危险度分层、核分裂象、肿瘤大小、Ki-67有关(P〈0.05),与患者年龄、性别、部位无关(P〉0.05)。结论危险度分层、核分裂象、肿瘤大小、Ki-67可作为预测胃肠道间质瘤预后的有用指标,中、高危险度组患者应定期复查,健全随访档案,积极治疗。 Objective To study the progression of gastrointcstinal stromal tumors(GISTs) acordingmedical record information resources. Methods The clinicopathology data of 76 patients with GIST were retrospectively reviewed. Results The patients all were at follow-up. The progression correlated with tumor sizes and mitotic cell count, and Ki-67 LI ( P 〈 0. 05 ), but no significant difference with locations ( P 〉 0. 05 ). Conclusion Tumor sizes and mitotic cell count, with Ki-67 LI can be used for assessing the risk of patients.
出处 《中国临床实用医学》 2010年第5期214-215,共2页 China Clinical Practical Medicine
关键词 胃肠道间质瘤 病历档案 预后 Gastrointestinal stromal tumors Medical record Progression
  • 相关文献

参考文献5

  • 1Suster S. Gastrointestinal stromal tumors. Semin Diagn Pathol 1996, 13:297-313.
  • 2中国胃肠道间质瘤病理共识意见[J].中华病理学杂志,2007,36(10):704-707. 被引量:110
  • 3Fletcher CD, Berman JJ, Corless CL, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002,33 ( 5 ) :459-465.
  • 4Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stmmal tumors. Science, 1998, 279 ( 5350 ) :577-580.
  • 5Miettinen M, Blay JY, Sobin LH. Mesenchymal tumors of the stomach//Hamihon SR, Aaltonen LA, ed. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon : IARC Press ,2000:62455.

二级参考文献24

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2Soft tissue sarcoma V. I. 2007. NCCN clinical practice guidelines in oncology [2007-05-27]. http://www. nccn. org.
  • 3Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350) :577-580.
  • 4Miettinen M, Blay JY, Sobin LH. Mesenchymal tumors of the stomach//Hamilton SR, Aaltonen LA, ed. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press, 2000:62-65.
  • 5Heinrich MC, Codess CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003,299(5607) :708-710.
  • 6Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer,2002, 38 (SupplS) : S39-S51.
  • 7Fletcher CD, Berman JJ, Corless CL, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol, 2002,33 (5) :459-465.
  • 8Miettinen M, Lasota J. KIT (CD117) : a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistoehem Mol Morphol,2005, 13 (3):205-220.
  • 9Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol, 2004, 22(18) : 3813-3825.
  • 10Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imafinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol, 2003, 21 (23) : 4342-4349.

共引文献109

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部